Investigators discuss classical head and neck squamous cell carcinoma immunotherapy, and highlight examples of clinical trials using CTLA-4 inhibitors and PD-1/PD-L1 related combination therapies.
[Molecular Therapy-Oncolytics]
Qin, Y., Zheng, X., Gao, W., Wang, B., & Wu, Y. (2021). Tumor microenvironment and immune-related therapies of Head and neck squamous cell carcinoma. Molecular Therapy - Oncolytics, 0(0). https://doi.org/10.1016/j.omto.2021.01.011 Cite
0